

February 14, 2018

To,

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : **531099**
Sub : **Outcome of Board Meeting**

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Thursday, February 14, 2019, inter alia, considered and approved the following:

1. Unaudited Financial Results for the quarter and half year ended December 31, 2018 along with Limited Review Report thereon.

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**



Abha Kapoor
Director (Finance) and Chief Financial Officer
DIN – 02799429

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Financial Results for the quarter ended December 31, 2018


(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		31-Dec-2018	30-Sep-2018	31-Dec-2017	31-Dec-2018	31-Dec-2017	31-Mar-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	10.94	9.09	0.00	29.12	195.72	229.80
II	Other Income	0.00	0.00	0.00	0.00	15.98	15.98
III	Total Income (I + II)	10.94	9.09	0.00	29.12	211.70	245.78
IV	Expenses:						
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	101.53	101.70
	Purchases of Stock in Trade	10.77	9.00	0.00	28.77	86.94	86.94
	Changes in inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	1.38	2.45	5.06	5.21	8.46	12.96
	Finance Costs	0.02	0.00	0.00	0.03	0.00	0.00
	Depreciation & amortisation expense	0.01	0.01	0.01	0.03	0.03	0.04
	Other Expenses	6.06	2.60	4.06	9.40	15.77	31.69
	Total Expenses (IV)	18.24	14.06	9.13	43.44	212.73	233.33
V	Profit / (loss) before exceptional items and tax (III-IV)	-7.30	-4.97	-9.13	-14.32	-1.03	12.45
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	28.82
VII	Profit / (loss) before tax (V-VI)	-7.30	-4.97	-9.13	-14.32	-1.03	-16.37
VIII	Tax Expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-7.30	-4.97	-9.13	-14.32	-1.03	-16.37
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	-7.30	-4.97	-9.13	-14.32	-1.03	-16.37
XIV	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-7.30	-4.97	-9.13	-14.32	-1.03	-16.37
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
	NOTES:						
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
2	The Segment - wise details are not applicable to the Company as the Company has no segments.						
3	The result is provisional and unaudited and subject to change, regrouping and restatement.						

For Rubra Medicaments Limited

Place: Mumbai
Date:- February 14, 2019


Abha Kapoor
 Director (Finance) & CFO
 DIN: 02799429



DINESH H AGARWAL & CO

CHARTERED ACCOUNTANTS

Limited Review Report of the Auditors

To,
The Board of Directors
Rubra Medicaments Limited
Mumbai


Sub: Limited Review Report

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Limited for the period ended December 31, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dinesh H Agarwal & Company
Chartered Accountants
Firm Registration No: ERN 129273W



Date: February 14, 2019
Place: Mumbai